Literature DB >> 19724192

CCR5 antagonism in HIV infection: ways, effects, and side effects.

Pierre Corbeau1, Jacques Reynes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19724192     DOI： 10.1097/QAD.0b013e32832e71cd

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  19 in total

Review 1.  Mendelian randomization: potential use of genetics to enable causal inferences regarding HIV-associated biomarkers and outcomes.

Authors:  Weijing He; John Castiblanco; Elizabeth A Walter; Jason F Okulicz; Sunil K Ahuja
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

2.  Maraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+ T cell recovery and gene expression.

Authors:  Nadejda Beliakova-Bethell; Sonia Jain; Christopher H Woelk; Mallory D Witt; Xiaoying Sun; Steven M Lada; Celsa A Spina; Miguel Goicoechea; Steffney E Rought; Richard Haubrich; Michael P Dubé
Journal:  Antiviral Res       Date:  2014-04-24       Impact factor: 5.970

3.  Induction of HIV-blocking anti-CCR5 IgA in Peyers's patches without histopathological alterations.

Authors:  Claudia Pastori; Lorenzo Diomede; Assunta Venuti; Gregory Fisher; Jonathan Jarvik; Morgane Bomsel; Francesca Sanvito; Lucia Lopalco
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

4.  Genotypic prediction of human immunodeficiency virus type 1 tropism by use of plasma and peripheral blood mononuclear cells in the routine clinical laboratory.

Authors:  Christian Paar; Maria Geit; Herbert Stekel; Jörg Berg
Journal:  J Clin Microbiol       Date:  2011-05-18       Impact factor: 5.948

5.  In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells.

Authors:  R Rossi; M Lichtner; A De Rosa; I Sauzullo; F Mengoni; A P Massetti; C M Mastroianni; V Vullo
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

6.  Synergistic combinations of the CCR5 inhibitor VCH-286 with other classes of HIV-1 inhibitors.

Authors:  Odalis Asin-Milan; Mohamed Sylla; Mohamed El-Far; Geneviève Belanger-Jasmin; Alpha Haidara; Julie Blackburn; Annie Chamberland; Cécile L Tremblay
Journal:  Antimicrob Agents Chemother       Date:  2014-09-29       Impact factor: 5.191

Review 7.  HIV Diagnosis and Treatment through Advanced Technologies.

Authors:  Hafiza Fizzah Zulfiqar; Aneeqa Javed; Bakht Afroze; Qurban Ali; Khadija Akbar; Tariq Nadeem; Muhammad Adeel Rana; Zaheer Ahmad Nazar; Idrees Ahmad Nasir; Tayyab Husnain
Journal:  Front Public Health       Date:  2017-03-07

8.  Epigenetic mechanisms, T-cell activation, and CCR5 genetics interact to regulate T-cell expression of CCR5, the major HIV-1 coreceptor.

Authors:  German G Gornalusse; Srinivas Mummidi; Alvaro A Gaitan; Fabio Jimenez; Veron Ramsuran; Anabela Picton; Kristen Rogers; Muthu Saravanan Manoharan; Nymisha Avadhanam; Krishna K Murthy; Hernan Martinez; Angela Molano Murillo; Zoya A Chykarenko; Richard Hutt; Demetre Daskalakis; Ludmila Shostakovich-Koretskaya; Salim Abdool Karim; Jeffrey N Martin; Steven G Deeks; Frederick Hecht; Elizabeth Sinclair; Robert A Clark; Jason Okulicz; Fred T Valentine; Neil Martinson; Caroline Tanya Tiemessen; Thumbi Ndung'u; Peter W Hunt; Weijing He; Sunil K Ahuja
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-11       Impact factor: 11.205

9.  CCR5: From Natural Resistance to a New Anti-HIV Strategy.

Authors:  Lucia Lopalco
Journal:  Viruses       Date:  2010-02-05       Impact factor: 5.818

Review 10.  Genetic variation in the chemokine receptor 5 gene and course of HIV infection; review on genetics and immunological aspect.

Authors:  M K Verma; S Shakya
Journal:  Genes Dis       Date:  2020-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.